A Review of the Evolution of Systemic Chemotherapy in Cancer

Clinical Colorectal Cancer

14, 1-10

DOI: 10.1016/j.clcc.2014.11.002

Citation Report

#	Article	IF	Citations
1	Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells. International Journal of Oncology, 2015, 47, 1663-1671.	1.4	52
2	miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4. Oncology Reports, 2015, 34, 1923-1932.	1.2	47
3	Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. Nanoscale, 2015, 7, 14080-14092.	2.8	68
4	5-Fluorouracil derivatives: a patent review (2012 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 1131-1144.	2.4	35
5	Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2015, 15, 1267-1281.	1.1	17
6	Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. OncoTargets and Therapy, 2016, Volume 9, 7503-7513.	1.0	31
7	miR-183 regulates autophagy and apoptosis in colorectal cancer through targeting of UVRAG. Oncotarget, 2016, 7, 4735-4745.	0.8	67
8	Darwinian Principles toward Multidrug-Resistant Cancer Cells. Journal of Applied Pharmacy, 2016, 8, .	0.1	1
9	Comparative evaluation of oncologic outcomes in colon cancer. Acta Cirurgica Brasileira, 2016, 31, 34-39.	0.3	3
10	Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancerassociated fibroblast accumulation. Oncotarget, 2016, 7, 48335-48345.	0.8	48
11	Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review. Oncotarget, 2016, 7, 66212-66225.	0.8	53
12	Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options. BioMed Research International, 2016, 2016, 1-12.	0.9	19
13	Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointestinal Cancer: Targets and Therapy, 2016, Volume 6, 21-30.	5.5	8
14	Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. Oncotarget, 2016, 7, 20612-20620.	0.8	21
15	Oridonin inhibits the proliferation of human colon cancer cells by upregulating BMP7 to activate p38 MAPK. Oncology Reports, 2016, 35, 2691-2698.	1.2	24
16	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells. Oncology Reports, 2016, 36, 1875-1885.	1.2	32
17	Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2). Tumor Biology, 2016, 37, 12231-12239.	0.8	36
18	Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer. Indian Journal of Surgical Oncology, 2016, 7, 177-187.	0.3	20

#	Article	IF	Citations
19	Engineered biomimetic nanoabsorbent for cellular detoxification of chemotherapeutics. RSC Advances, 2016, 6, 33003-33008.	1.7	27
20	Novel porphyrinâ€“Schiff base conjugates: synthesis, characterization and in vitro photodynamic activities. RSC Advances, 2016, 6, 45681-45688.	1.7	11
21	A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-Î±-2b in patients with CEA-expressing carcinomas. Cancer Immunology, Immunotherapy, 2016, 65, 1353-1364.	2.0	31
22	BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer. Clinical Cancer Research, 2016, 22, 5058-5067.	3.2	21
23	Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. Biochemical Pharmacology, 2016, 121, 8-17.	2.0	66
24	Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1Î±. Journal of Zhejiang University: Science B, 2016, 17, 672-682.	1.3	26
25	Hepatocellular carcinoma stem cell-like cells are enriched following low-dose 5-fluorouracil chemotherapy. Oncology Letters, 2016, 12, 2511-2516.	0.8	4
26	Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta OncolÃ³gica, 2016, 55, 1273-1280.	0.8	62
27	Colorectal Cancer. Gastroenterology Clinics of North America, 2016, 45, 459-476.	1.0	40
28	Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Acta OncolÃ³gica, 2016, 55, 1227-1235.	0.8	31
29	Oxaliplatin-based chemotherapy combined with traditional medicines for neutropenia in colorectal cancer: A meta-analysis of the contributions of specific plants. Critical Reviews in Oncology/Hematology, 2016, 105, 18-34.	2.0	24
30	Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis. Cancer Epidemiology, 2016, 45, 71-81.	0.8	57
31	Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2016, 12, 303-313.	1.0	0
32	UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 119-130.	1.1	33
33	Personalized immunotherapy in colorectal cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 267-277.	0.4	2
34	Biomaterial-based regional chemotherapy: Local anticancer drug delivery to enhance chemotherapy and minimize its side-effects. Materials Science and Engineering C, 2016, 62, 927-942.	3.8	142
35	From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy. Clinical Colorectal Cancer, 2016, 15, 104-115.	1.0	20
36	TAS-102: a novel antimetabolite for the 21st century. Future Oncology, 2016, 12, 153-163.	1.1	17

#	Article	IF	Citations
37	Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. Gastroenterology, 2016, 150, 1135-1146.	0.6	92
38	Baseline [18F]FMISO Î¼PET as a Predictive Biomarker for Response to HIF-1Î± Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model. Molecular Imaging and Biology, 2016, 18, 606-616.	1.3	11
39	Screening and In Vitro Evaluation of Mucoadhesive Thermoresponsive System Containing Methylene Blue for Local Photodynamic Therapy of Colorectal Cancer. Pharmaceutical Research, 2016, 33, 776-791.	1.7	31
40	Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties. European Journal of Medicinal Chemistry, 2016, 107, 233-244.	2.6	56
41	MicroRNAs are important regulators of drug resistance in colorectal cancer. Biological Chemistry, 2017, 398, 929-938.	1.2	52
42	Gambogic acid potentiates the chemosensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting proliferation and inducing apoptosis. Experimental and Therapeutic Medicine, 2017, 13, 662-668.	0.8	13
43	Second-line systemic therapy for metastatic colorectal cancer. The Cochrane Library, 2017, 1, CD006875.	1.5	26
44	New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets. Autophagy, 2017, 13, 781-819.	4.3	117
45	Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 expression. Human Pathology, 2017, 63, 33-39.	1.1	22
46	Baicalein attenuates vinorelbine-induced vascular endothelial cell injury and chemotherapeutic phlebitis in rabbits. Toxicology and Applied Pharmacology, 2017, 318, 23-32.	1.3	20
47	Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin. Oncology Reports, 2017, 37, 1815-1825.	1.2	47
48	The role of MRP1 in the multidrug resistance of colorectal cancer. Oncology Letters, 2017, 13, 2471-2476.	0.8	25
49	Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer. Oncology Letters, 2017, 13, 2089-2096.	0.8	10
50	Anti-EGFR and Anti-VEGF Agents in First-Line Therapy for Advanced Colorectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 257-263.	1.0	0
51	Overexpression of PER3 Inhibits Self-Renewal Capability and Chemoresistance of Colorectal Cancer Stem-Like Cells via Inhibition of Notch and Î²-Catenin Signaling. Oncology Research, 2017, 25, 709-719.	0.6	42
52	Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion. Chemotherapy, 2017, 62, 295-300.	0.8	4
53	Novel proapoptotic agent SM-1 enhances the inhibitory effect of 5-fluorouracil on colorectal cancer cells in vitro and in vivo. Oncology Letters, 2017, 13, 4762-4768.	0.8	4
54	A nomogram to predict 5-fluorouracil toxicity. Anti-Cancer Drugs, 2017, 28, 551-556.	0.7	10

#	Article	IF	Citations
55	Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Investigational New Drugs, 2017, 35, 491-498.	1.2	7
56	Current and future biomarkers in the treatment of colorectal cancer. Acta Clinica Belgica, 2017, 72, 103-115.	0.5	30
57	Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease. CardioVascular and Interventional Radiology, 2017, 40, 496-501.	0.9	15
58	Overexpression of long nonâ€'coding RNA colon cancerâ€'associated transcript 2 is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer. Oncology Letters, 2017, 14, 6907-6914.	0.8	21
59	Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1161-1169.	1.1	5
60	Tailored Treatment of Colorectal Cancer: Surgical, Molecular, and Genetic Considerations. Clinical Medicine Insights: Oncology, 2017, 11, 117955491769076.	0.6	31
61	Towards personalized medicine of colorectal cancer. Critical Reviews in Oncology/Hematology, 2017, 118, 70-78.	2.0	42
62	A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. Cell Reports, 2017, 20, 999-1015.	2.9	77
63	Terpinen-4-ol inhibits colorectal cancer growth via reactive oxygen species. Oncology Letters, 2017, 14, 2015-2024.	0.8	32
64	A Novel Role for MiR-520a-3p in Regulating EGFR Expression in Colorectal Cancer. Cellular Physiology and Biochemistry, 2017, 42, 1559-1574.	1.1	22
65	Alcoholic extracts of Epilobium, Urtica dioica and Evernia prunastri with 5-fluorouracil in controlling murine colon carcinoma cell growth in vitro. Oriental Pharmacy and Experimental Medicine, 2017, 17, 325-336.	1.2	3
66	From academia to industry: a road more travelled. Annals of Oncology, 2017, 28, 2312-2314.	0.6	4
67	Preparation and characterization of bioadhesive system containing hypericin for local photodynamic therapy. Photodiagnosis and Photodynamic Therapy, 2017, 19, 284-297.	1.3	34
68	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. Journal of Vascular and Interventional Radiology, 2017, 28, 1210-1223.e3.	0.2	103
69	Functionalization of mixed ligand metal-organic frameworks as the transport vehicles for drugs. Journal of Colloid and Interface Science, 2017, 486, 128-135.	5.0	99
70	Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update. Frontiers in Pharmacology, 2017, 8, 736.	1.6	20
71	Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs. BioMed Research International, 2017, 2017, 1-38.	0.9	40
72	Changes of liver hemodynamic and elastography parameters in patients with colorectal liver metastases receiving preoperative chemotherapy: â€œa note of cautionâ€• World Journal of Surgical Oncology, 2017, 15, 224.	0.8	5

#	Article	IF	Citations
73	HLA-G 3â€²UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 1366.	1.8	13
74	Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer. Oncotarget, 2017, 8, 100668-100677.	0.8	8
75	Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update. Expert Opinion on Pharmacotherapy, 2018, 19, 795-807.	0.9	1
76	Suppress orthotopic colon cancer and its metastasis through exact targeting and highly selective drug release by a smart nanomicelle. Biomaterials, 2018, 161, 144-153.	5.7	36
77	Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells. International Journal of Molecular Medicine, 2018, 41, 1447-1454.	1.8	17
78	NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy. Genes Chromosomes and Cancer, 2018, 57, 268-277.	1.5	16
79	Tumor Microenvironmentâ€Enabled Nanotherapy. Advanced Healthcare Materials, 2018, 7, e1701156.	3.9	158
80	iTRAQ Quantitative Proteomic Profiling and MALDIâ€“MSI of Colon Cancer Spheroids Treated with Combination Chemotherapies in a 3D Printed Fluidic Device. Analytical Chemistry, 2018, 90, 1423-1430.	3.2	34
81	Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells. Cancer Medicine, 2018, 7, 196-207.	1.3	22
82	Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncology Letters, 2019, 17, 215-220.	0.8	2
83	Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. The Cochrane Library, 2018, 2018, CD012326.	1.5	5
84	Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition. Neoplasia, 2018, 20, 1236-1245.	2.3	12
85	The Issue of Survival After Colorectal Liver Metastasis Surgery: Parenchyma Sparing vs. Radicality. Anticancer Research, 2018, 38, 6431-6438.	0.5	5
86	Administration of High-Dose Vitamin C and Irinotecan Ameliorates Colorectal Cancer Induced by Azoxymethane and Dextran Sodium Sulfate in Mice. Biological and Pharmaceutical Bulletin, 2018, 41, 1797-1803.	0.6	8
87	Galactosylated Chitosan-Functionalized Mesoporous Silica Nanoparticle Loading by Calcium Leucovorin for Colon Cancer Cell-Targeted Drug Delivery. Molecules, 2018, 23, 3082.	1.7	24
88	Base excision repair capacity as a determinant of prognosis and therapy response in colon cancer patients. DNA Repair, 2018, 72, 77-85.	1.3	27
89	Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells. International Journal of Molecular Sciences, 2018, 19, 2915.	1.8	10
90	phorbol ester-induced metastatic activity of colorectal cancer cells through upregulation of heme oxygenase-1. European Journal of Pharmacology, 2018, 841, 1-9.	1.7	7

#	Article	IF	Citations
91	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. Frontiers in Pharmacology, 2018, 9, 1101.	1.6	8
92	Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options. Current Treatment Options in Oncology, 2018, 19, 49.	1.3	41
93	Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 667 Td (glycol)â€“poly(lactid Anti-Cancer Drugs, 2018, 29, 637-645.	0.7	13
94	Retrospective study of epidemiological, clinicopathological and biological profils of 62 colorectal cancers cases in Jijel provence (Algeria). Journal of Fundamental and Applied Sciences, 2018, 10, 59.	0.2	1
95	Modernâ€day palliative chemotherapy for metastatic colorectal cancer: does colonic resection affect survival?. ANZ Journal of Surgery, 2018, 88, E772-E777.	0.3	5
96	Inhibiting ABCG2 could potentially enhance the efficacy of hypericin-mediated photodynamic therapy in spheroidal cell models of colorectal cancer. Photodiagnosis and Photodynamic Therapy, 2018, 23, 221-229.	1.3	20
97	Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. Journal of Molecular Diagnostics, 2018, 20, 664-676.	1.2	19
98	A Reconstruction Method for the Estimation of Temperatures of Multiple Sources Applied for Nanoparticle-Mediated Hyperthermia. Molecules, 2018, 23, 670.	1.7	4
99	Synthesis, Anti-Proliferative Activity Evaluation and 3D-QSAR Study of Naphthoquinone Derivatives as Potential Anti-Colorectal Cancer Agents. Molecules, 2018, 23, 186.	1.7	10
100	Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. Journal of Surgical Research, 2018, 227, 158-167.	0.8	8
101	Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. Scientific Reports, 2018, 8, 7386.	1.6	12
102	Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. Future Oncology, 2018, 14, 2097-2102.	1.1	4
103	miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer. Frontiers in Pharmacology, 2018, 9, 846.	1.6	27
104	Meta-analysis of oncologic effect of primary tumor resection in patients with unresectable stage IV colorectal cancer in the era of modern systemic chemotherapy. Annals of Surgical Treatment and Research, 2018, 95, 64.	0.4	16
105	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e687-e697.	1.0	15
106	Cyclophilin B induces chemoresistance by degrading wildâ€type p53 via interaction with MDM2 in colorectal cancer. Journal of Pathology, 2018, 246, 115-126.	2.1	21
107	Induced miRâ€31 by 5â€fluorouracil exposure contributes to the resistance in colorectal tumors. Cancer Science, 2019, 110, 2540-2548.	1.7	14
108	BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15469-15474.	3.3	31

#	Article	IF	Citations
109	Highly Biocompatible Functionalized Layerâ€byâ€Layer Ginger Lipid Nano Vectors Targeting Pâ€Selectin for Delivery of Doxorubicin to Treat Colon Cancer. Advanced Therapeutics, 2019, 2, 1900129.	1.6	17
110	ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective singleâ€center clinical utility studyâ€"PRECISE study. Cancer Medicine, 2019, 8, 6305-6314.	1.3	6
111	Evaluation and Clinical Significance of Jagged-1-activated Notch Signaling by APEX1 in Colorectal Cancer. Anticancer Research, 2019, 39, 6097-6105.	0.5	12
112	Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2. Scientific Reports, 2019, 9, 16647.	1.6	8
113	Expanding the Arsenal of Pt^{IV} Anticancer Agents: Multiâ€action Pt^{IV} Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angewandte Chemie, 2019, 131, 18386-18391.	1.6	11
114	Expanding the Arsenal of Pt^{IV} Anticancer Agents: Multiâ€action Pt^{IV} Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angewandte Chemie - International Edition, 2019, 58, 18218-18223.	7.2	47
115	Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 370.	3.5	22
116	Treatment selection bias for chemotherapy persists in colorectal cancer patient cohort studies even in comprehensive propensity score analyses . Clinical Epidemiology, 2019, Volume 11, 821-832.	1.5	11
117	Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies. Antioxidants, 2019, 8, 407.	2.2	40
118	RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance. PLoS ONE, 2019, 14, e0222392.	1.1	19
119	miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L. Experimental Cell Research, 2019, 385, 111597.	1.2	39
120	The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo. Molecular Cancer Therapeutics, 2019, 18, 1973-1984.	1.9	7
121	Complete response with fluorouracil and irinotecan with a BRAF^{V600E} and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report. OncoTargets and Therapy, 2019, Volume 12, 443-447.	1.0	10
122	CMAB009 plus irinotecan versus irinotecanâ€only as secondâ€line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wildâ€type metastatic colorectal cancer patients: promising findings from a prospective, openâ€label, randomized, phase III trial. Cancer Communications, 2019, 39, 1-13.	3.7	6
123	A systematic analysis of genomics-based modeling approaches for prediction of drug response to cytotoxic chemotherapies. BMC Medical Genomics, 2019, 12, 87.	0.7	10
124	Identification of a 13â€'geneâ€'based classifier as a potential biomarker to predict the effects of fluorouracilâ€'based chemotherapy in colorectal cancer. Oncology Letters, 2019, 17, 5057-5063.	0.8	4
125	Activity of base analogues (5-fluorouracil, 5-flucytosine) against planktonic cells and mature biofilm of Candida yeast. Effect of combination with folinic acid. Journal De Mycologie Medicale, 2019, 29, 147-153.	0.7	2
126	Highly stable near-infrared dye conjugated cerasomes for fluorescence imaging-guided synergistic chemo-photothermal therapy of colorectal cancer. Biomaterials Science, 2019, 7, 2873-2888.	2.6	15

#	Article	IF	Citations
127	Ziyuglycoside II induces caspases-dependent and caspases-independent apoptosis in human colon cancer cells. Toxicology in Vitro, 2019, 59, 255-262.	1.1	19
128	Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. Oncology Letters, 2019, 17, 3890-3898.	0.8	13
129	RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. International Journal of Cancer, 2019, 145, 2580-2593.	2.3	26
130	RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 957-968.	1.9	32
131	A Review on the Scope of Photothermal Therapyâ€“Based Nanomedicines in Preclinical Models of Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, e200-e209.	1.0	61
132	On-chip combined radiotherapy and chemotherapy testing on soft-tissue sarcoma spheroids to study cell death using flow cytometry and clonogenic assay. Scientific Reports, 2019, 9, 2214.	1.6	20
133	Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial. BMJ Open, 2019, 9, e034508.	0.8	17
134	ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials. International Journal of Colorectal Disease, 2019, 34, 2143-2150.	1.0	14
135	Developing a Drug Screening Platform: MALDI-Mass Spectrometry Imaging of Paper-Based Cultures. Analytical Chemistry, 2019, 91, 15370-15376.	3.2	19
136	Xanthohumol inhibits colorectal cancer cells via downregulation of Hexokinases II-mediated glycolysis. International Journal of Biological Sciences, 2019, 15, 2497-2508.	2.6	58
137	Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/Î²-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation. Journal of Medicinal Chemistry, 2019, 62, 11151-11164.	2.9	28
138	Adjuvant Therapy for Stages II and III Colon Cancer: Risk Stratification, Treatment Duration, and Future Directions. Current Oncology, 2019, 26, 43-52.	0.9	28
139	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the â€˜Uâ€™ out of â€˜CUPâ€™. British Journal of Cancer, 2019, 120, 141-153.	2.9	71
140	Meta-analysis of oncological outcomes of sigmoid cancers: A hidden epidemic of R1 â€œpalliativeâ€• resections. European Journal of Surgical Oncology, 2019, 45, 489-497.	0.5	3
141	Electrospun nanofibers for local anticancer therapy: Review of in vivo activity. International Journal of Pharmaceutics, 2019, 558, 268-283.	2.6	36
142	Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo/thermotherapy delivery system for local treatment of colon cancer. Biomaterials, 2019, 197, 86-100.	5.7	104
143	Toward Multi-Targeted Platinum and Ruthenium Drugsâ€”A New Paradigm in Cancer Drug Treatment Regimens?. Chemical Reviews, 2019, 119, 1058-1137.	23.0	463
144	Functional Polymorphisms in DNA Repair Genes Are Associated with Sporadic Colorectal Cancer Susceptibility and Clinical Outcome. International Journal of Molecular Sciences, 2019, 20, 97.	1.8	20

#	Article	IF	Citations
145	Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells. Cancer Biology and Therapy, 2019, 20, 284-294.	1.5	13
146	In vivo metabolic and SHG imaging for monitoring of tumor response to chemotherapy. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 47-55.	1.1	26
147	Reactive oxygen species in colorectal cancer: The therapeutic impact and its potential roles in tumor progression via perturbation of cellular and physiological dysregulated pathways. Journal of Cellular Physiology, 2019, 234, 10072-10079.	2.0	33
148	A molecular basis for the synergy between 17â€'allylaminoâ€'17â€'demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression. Gene, 2019, 684, 30-38.	1.0	23
149	Evaluation of a new histological grading system for assessing the response to chemotherapy of peritoneal metastases from colorectal cancer: A mouse model study. European Journal of Surgical Oncology, 2020, 46, 160-165.	0.5	9
150	Tumor cell membrane-coated biomimetic nanoplatform for homologous targeted therapy of colorectal carcinoma. International Journal of Polymeric Materials and Polymeric Biomaterials, 2020, 69, 1157-1166.	1.8	8
151	NSG mice as hosts for oncological precision medicine. Laboratory Investigation, 2020, 100, 27-37.	1.7	26
152	Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. Oncologist, 2020, 25, 33-45.	1.9	87
153	The Impact of CRISPR-Cas9 on Age-related Disorders: From Pathology to Therapy. , 2020, 11, 895.		8
154	Ferroptosis-driven nanotherapeutics for cancer treatment. Journal of Controlled Release, 2020, 319, 322-332.	4.8	130
155	National statistics about resection of the primary tumor in asymptomatic patients with Stage IV colorectal cancer and unresectable metastases. Need for improvement in data collection. A systematic review with meta-analysis. Surgical Oncology, 2020, 33, 11-18.	0.8	15
156	Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer. Clinical and Translational Oncology, 2020, 22, 1105-1116.	1.2	26
157	5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. , 2020, 206, 107447.		449
158	18F-FDG PET/MRI for Rectal Cancer TNM Restaging After Preoperative Chemoradiotherapy: Initial Experience. Diseases of the Colon and Rectum, 2020, 63, 310-318.	0.7	27
159	New selective thiolate gold(i) complexes inhibit the proliferation of different human cancer cells and induce apoptosis in primary cultures of mouse colon tumors. Dalton Transactions, 2020, 49, 1915-1927.	1.6	17
160	Integration of genetic variants and gene network for drug repurposing in colorectal cancer. Pharmacological Research, 2020, 161, 105203.	3.1	26
161	Characterising a PDMS based 3D cell culturing microfluidic platform for screening chemotherapeutic drug cytotoxic activity. Scientific Reports, 2020, 10, 15915.	1.6	27
162	Drug-Induced Interstitial Pneumonia due to Application of FOLFOX as Adjuvant Chemotherapy after Rectal Cancer Surgery: A Case Report and Literature Review. Case Reports in Oncology, 2020, 13, 768-773.	0.3	2

#	Article	IF	Citations
163	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open, 2020, 5, e001040.	2.0	6
164	The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC). Cancers, 2020, 12, 3336.	1.7	96
165	Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review. Radiation Oncology, 2020, 15, 262.	1.2	38
166	Distant Metastasis in Colorectal Cancer Patientsâ€"Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 5255.	1.8	38
167	Individualized prediction of survival benefit from primary tumor resection for patients with unresectable metastatic colorectal cancer. World Journal of Surgical Oncology, 2020, 18, 193.	0.8	5
168	The clinical effect of Kampo medicine in multimodal treatment for Gastrointestinal Cancer in Japan. Journal of Cancer, 2020, 11, 5390-5394.	1.2	5
169	A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway. BMC Cancer, 2020, 20, 685.	1.1	14
170	Lactobacillus-derived metabolites enhance the antitumor activity of 5-FU and inhibit metastatic behavior in 5-FU-resistant colorectal cancer cells by regulating claudin-1 expression. Journal of Microbiology, 2020, 58, 967-977.	1.3	14
171	Development of a Model for Predicting Early Discontinuation of Adjuvant Chemotherapy in Stage III Colon Cancer. JCO Clinical Cancer Informatics, 2020, 4, 972-984.	1.0	4
172	Circ_0007031 enhances tumor progression and promotes 5-fluorouracil resistance in colorectal cancer through regulating miR-133b/ABCC5 axis. Cancer Biomarkers, 2020, 29, 531-542.	0.8	27
173	Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel . International Journal of Nanomedicine, 2020, Volume 15, 6737-6748.	3.3	45
174	The effect of miRNA and autophagy on colorectal cancer. Cell Proliferation, 2020, 53, e12900.	2.4	43
175	Dual Targeting of Cell Growth and Phagocytosis by Erianin for Human Colorectal Cancer . Drug Design, Development and Therapy, 2020, Volume 14, 3301-3313.	2.0	19
176	5-Fluorouracil Conversion Pathway Mutations in Gastric Cancer. Biology, 2020, 9, 265.	1.3	5
177	The Analysis of Differentially Expressed circRNAs Under the Antiproliferative Effect From 5-Fluorouracil on Osteosarcoma Cells. Technology in Cancer Research and Treatment, 2020, 19, 153303382096421.	0.8	3
178	Superior Effect of the Combination of Carbon-Ion Beam Irradiation and 5-Fluorouracil on Colorectal Cancer Stem Cells in vitro and in vivo . OncoTargets and Therapy, 2020, Volume 13, 12625-12635.	1.0	5
179	6-Shogaol enhances the anticancer effect of 5-fluorouracil, oxaliplatin, and irinotecan via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions. BMC Complementary Medicine and Therapies, 2020, 20, 141.	1.2	23
180	Influence of ABCBâ€1, ERCCâ€1 and ERCCâ€2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 617-627.	0.7	4

#	Article	IF	Citations
181	Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review. Molecules, 2020, 25, 2270.	1.7	12
182	In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors. Journal of Controlled Release, 2020, 324, 146-155.	4.8	9
183	Simulating the human colorectal cancer microenvironment in 3D tumor-stroma co-cultures in vitro and in vivo. Scientific Reports, 2020, 10, 9832.	1.6	34
184	Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC Cancer, 2020, 20, 560.	1.1	19
185	Prodigiosin impairs autophagosome-lysosome fusion that sensitizes colorectal cancer cells to 5-fluorouracil-induced cell death. Cancer Letters, 2020, 481, 15-23.	3.2	25
186	Recellularized Colorectal Cancer Patient-Derived Scaffolds as In Vitro Pre-Clinical 3D Model for Drug Screening. Cancers, 2020, 12, 681.	1.7	32
187	Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules. Inorganic Chemistry, 2020, 59, 5182-5193.	1.9	37
188	Surveillance Colonoscopy in Older Stage I Colon Cancer Patients and the Association With Colon Cancer-Specific Mortality. American Journal of Gastroenterology, 2020, 115, 924-933.	0.2	6
189	Pro-apoptotic action of protein-carbohydrate fraction isolated from coelomic fluid of the earthworm Dendrobaena veneta against human colon adenocarcinoma cells. Biomedicine and Pharmacotherapy, 2020, 126, 110035.	2.5	16
190	S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer. Pharmacological Research, 2020, 155, 104717.	3.1	24
191	Integrating Genome-Wide Association Studies and Gene Expression Profiles With Chemical-Genes Interaction Networks to Identify Chemicals Associated With Colorectal Cancer. Frontiers in Genetics, 2020, 11, 385.	1.1	4
192	Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019. Metallomics, 2020, 12, 876-890.	1.0	9
193	Orally delivered targeted nanotherapeutics for the treatment of colorectal cancer. Expert Opinion on Drug Delivery, 2020, 17, 781-790.	2.4	13
194	Oxidative Damage in Sporadic Colorectal Cancer: Molecular Mapping of Base Excision Repair Glycosylases in Colorectal Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 2473.	1.8	28
195	Hyaluronic a<scp>cidâ€“doxorubicin</scp> nanoparticles for targeted treatment of colorectal cancer. Bioengineering and Translational Medicine, 2021, 6, e10166.	3.9	19
196	Curcumin: A therapeutic strategy for colorectal cancer?. Seminars in Cancer Biology, 2021, 73, 321-330.	4.3	31
197	Pumpless, unidirectional microphysiological system for testing <scp>metabolismâ€dependent</scp> chemotherapeutic toxicity. Biotechnology Progress, 2021, 37, e3105.	1.3	9
198	Complete mesocolic excision versus conventional hemicolectomy in patients with right colon cancer: a systematic review and meta-analysis. International Journal of Colorectal Disease, 2021, 36, 881-892.	1.0	43

#	Article	IF	Citations
199	Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. Cancer Chemotherapy and Pharmacology, 2021, 87, 31-41.	1.1	3
200	The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Annals of Oncology, 2021, 32, 269-278.	0.6	14
201	Interleukin 8 as predictive factor for response to chemotherapy in colorectal cancer patients. Acta Clinica Belgica, 2021, 76, 113-118.	0.5	10
202	Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110063.	1.4	5
203	Colorectal cancer and its targeting. , 2021, , 373-382.		0
204	Potential of Gold Candidates against Human Colon Cancer. Mini-Reviews in Medicinal Chemistry, 2021, 21, 69-78.	1.1	2
205	Unexpected solution behaviour of ester-functionalized half-sandwich Ru(ii) and Ir(iii) complexes. Dalton Transactions, 2021, 50, 8017-8028.	1.6	3
206	Pt(<scp>iv</scp>) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid: synthesis, characterization, cell penetration properties and antitumor activity. Dalton Transactions, 2021, 50, 4663-4672.	1.6	11
207	Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective. Cancer Control, 2021, 28, 107327482110387.	0.7	8
208	Prognostic Value of Autophagy, Microsatellite Instability, and KRAS Mutations in Colorectal Cancer. Journal of Cancer, 2021, 12, 3515-3528.	1.2	9
209	Antitumor Effect of 5-Fluorouracil-Loaded Liposomes Containing n-3 Polyunsaturated Fatty Acids in Two Different Colorectal Cancer Cell Lines. AAPS PharmSciTech, 2021, 22, 36.	1.5	6
210	Recent Therapeutic Strategies for the Treatment of Colon Cancer. , 2021, , 73-90.		0
211	Intracellular Paclitaxel Delivery Facilitated by a Dual-Functional CPP with a Hydrophobic Hairpin Tail. ACS Applied Materials & Interfaces, 2021, 13, 4853-4860.	4.0	11
212	Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy. Cell, 2021, 184, 226-242.e21.	13.5	258
213	The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. International Journal of Molecular Sciences, 2021, 22, 2463.	1.8	10
214	Medicinal inorganic chemistry: an updated review on the status of metallodrugs and prominent metallodrug candidates. Reviews in Inorganic Chemistry, 2022, 42, 29-52.	1.8	19
215	Overexpression of long non-coding RNA urothelial carcinoma associated 1 causes paclitaxel (Taxol) resistance in colorectal cancer cells by promoting glycolysis. Journal of Chemotherapy, 2021, 33, 409-419.	0.7	5
216	Cannabinoids pharmacological effects are beyond the palliative effects: CB2 cannabinoid receptor agonist induced cytotoxicity and apoptosis in human colorectal cancer cells (HT-29). Molecular and Cellular Biochemistry, 2021, 476, 3285-3301.	1.4	9

#	Article	IF	Citations
217	The effectiveness of plasma miRâ€'33aâ€'5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy. Oncology Letters, 2021, 21, 489.	0.8	5
218	Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients. Frontiers in Oncology, 2021, 11, 651380.	1.3	12
219	Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. Materials, 2021, 14, 2440.	1.3	14
220	Synergistic Interaction between 5-FU and an Analog of Sulforaphaneâ€"2-Oxohexyl Isothiocyanateâ€"In an In Vitro Colon Cancer Model. Molecules, 2021, 26, 3019.	1.7	6
221	The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy. Oncogene, 2021, 40, 3974-3988.	2.6	25
222	In vitroAnti-colorectal Cancer Potential of the Medicinal MushroomGanoderma neo-japonicumImazeki in Hyperglycemic Condition: Impact on Oxidative Stress, Cell Cycle and Apoptosis. Nutrition and Cancer, 2022, 74, 978-995.	0.9	5
223	Selective cytotoxicity of cyclometalated gold(III) complexes on Caco-2 cells is mediated by G2/M cell cycle arrest. Metallomics, 2021, 13, .	1.0	6
224	Synthesis and Antiproliferative and Antilipolytic Activities of a Series of 1,3- and	0.3	3
225	Targeting breast cancer using pirarubicin-loaded vasoactive intestinal peptide grafted sterically stabilized micelles. European Journal of Pharmaceutical Sciences, 2021, 162, 105830.	1.9	7
226	Potential Role of Traditional Chinese Medicines by Wnt/Î²-Catenin Pathway Compared With Targeted Small Molecules in Colorectal Cancer Therapy. Frontiers in Pharmacology, 2021, 12, 690501.	1.6	8
227	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treatment Reviews, 2021, 98, 102218.	3.4	33
228	Advances on colorectal cancer 3D models: The needed translational technology for nanomedicine screening. Advanced Drug Delivery Reviews, 2021, 175, 113824.	6.6	27
229	A methylation-based prognostic model predicts survival in patients with colorectal cancer. Journal of Gastrointestinal Oncology, 2021, 12, 1590-1600.	0.6	4
230	Colossolactone-G synergizes the anticancer properties of 5-fluorouracil and gemcitabine against colorectal cancer cells. Biomedicine and Pharmacotherapy, 2021, 140, 111730.	2.5	11
231	Nanocarriers as a Tool for the Treatment of Colorectal Cancer. Pharmaceutics, 2021, 13, 1321.	2.0	13
232	A folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal cancer. International Journal of Pharmaceutics, 2021, 606, 120888.	2.6	23
233	Importance of Circ0009910 in colorectal cancer pathogenesis as a possible regulator of miR-145 and PEAK1. World Journal of Surgical Oncology, 2021, 19, 265.	0.8	10
234	Personalized medicine: Stem cells in colorectal cancer treatment. Biomedicine and Pharmacotherapy, 2021, 141, 111821.	2.5	16

#	Article	IF	Citations
235	Restoration of miR-124 serves as a promising therapeutic approach in CRC by affecting CDK6 which is itself a prognostic and diagnostic factor. Gene Reports, 2021, 24, 101274.	0.4	1
236	MS imaging of multicellular tumor spheroids and organoids as an emerging tool for personalized medicine and drug discovery. Journal of Biological Chemistry, 2021, 297, 101139.	1.6	17
237	Antiproliferative and palliative activity of flavonoids in colorectal cancer. Biomedicine and Pharmacotherapy, 2021, 143, 112241.	2.5	151
238	The association of comorbidities with administration of adjuvant chemotherapy in stage III colon cancer patients: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098652.	1.4	6
239	[18F]FDG PET/MRI in rectal cancer. Annals of Nuclear Medicine, 2021, 35, 281-290.	1.2	20
240	Yin Yang 1 regulation of tumor cell resistance to chemotherapeutic drugs. , 2021, , 251-268.		0
241	Synergistic anticancer effect of docosahexaenoic acid and isoliquiritigenin on human colorectal cancer cells through ROS-mediated regulation of the JNK and cytochrome c release. Molecular Biology Reports, 2021, 48, 1171-1180.	1.0	7
242	Recent progress on nanomedicine-induced ferroptosis for cancer therapy. Biomaterials Science, 2021, 9, 5092-5115.	2.6	38
243	Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Molecular Cancer, 2021, 20, 10.	7.9	70
244	Engineering Protein Venoms as Selfâ€Assembling CXCR4â€Targeted Cytotoxic Nanoparticles. Particle and Particle Systems Characterization, 2020, 37, 2000040.	1.2	9
245	Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?. Journal of Chemotherapy, 2020, 32, 310-322.	0.7	7
246	5-Fluorouracil Management of Oculofacial Scars: A Systematic Literature Review. Ophthalmic Plastic and Reconstructive Surgery, 2020, 36, 222-230.	0.4	8
247	Downregulation of miR-222-3p Reverses Doxorubicin-Resistance in LoVo Cells Through Upregulating Forkhead Box Protein P2 (FOXP2) Protein. Medical Science Monitor, 2019, 25, 2169-2178.	0.5	18
248	Long Non-Coding RNA (lncRNA) BMP/OP-Responsive Gene (BORG) Promotes Development of Chemoresistance of Colorectal Cancer Cells to Carboplatin. Medical Science Monitor, 2020, 26, e919103.	0.5	5
249	DNA Base Bioisosteres, Bis-benzoxazoles, Exert Anti-proliferative Effect on Human Prostate and Breast Cancer Cells. Journal of the Turkish Chemical Society, Section A: Chemistry, 0, , 1145-1152.	0.4	7
250	Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer. Oncotarget, 2017, 8, 48012-48026.	0.8	39
251	The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. Oncotarget, 2017, 8, 110904-110913.	0.8	18
252	Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. Oncotarget, 2016, 7, 13269-13284.	0.8	38

#	Article	IF	Citations
253	Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer. Combinatorial Chemistry and High Throughput Screening, 2019, 21, 718-724.	0.6	12
254	Research Progress of Axl Inhibitors. Current Topics in Medicinal Chemistry, 2019, 19, 1338-1349.	1.0	10
255	Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer. World Journal of Gastroenterology, 2016, 22, 490.	1.4	38
256	Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil. World Journal of Gastroenterology, 2018, 24, 475-483.	1.4	9
257	Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells. Saudi Journal of Gastroenterology, 2017, 23, 34.	0.5	8
258	Colorectal liver metastases: Current management and future perspectives. World Journal of Clinical Oncology, 2020, 11, 761-808.	0.9	98
259	High cytoplasmic YAP1 expression predicts a poor prognosis in patients with colorectal cancer. PeerJ, 2020, 8, e10397.	0.9	6
260	Role of Vitamin D in Colorectal Cancer: A Holistic Approach and Review of the Clinical Utility. Cureus, 2020, 12, e10734.	0.2	6
261	Pleckstrin 2 is a potential drug target for colorectal carcinoma with activation of APC/Î²â€˜catenin. Molecular Medicine Reports, 2021, 24, .	1.1	2
262	Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers, 2021, 13, 5059.	1.7	39
263	Comparison of the Eight-Hour With the 22-Hour Infusion of 5-Fluorouracil, in the FOLFOX Chemotherapy of Colon Cancer: A Retrospective Study. Jundishapur Journal of Natural Pharmaceutical Products, 2016, 11, .	0.3	0
265	Responsive Nanogels for Anti-cancer Therapy. RSC Smart Materials, 2017, , 210-260.	0.1	2
266	Management of Patients with Acute Large Bowel Obstruction from Colon Cancer. Difficult Decisions in Surgery: an Evidence-based Approach, 2017, , 121-138.	0.0	0
270	BISBENZOXAZOLE DERIVATIVES HAD ANTI-PROLIFERATIVE EFFECT ON HUMAN CANCER CELLS. EskiÅŸehir Teknik Ãœniversitesi Bilim Ve Teknoloji Dergisi - C YaÅŸam Bilimleri Ve Biyoteknoloji, 2019, 8, 203-211.	0.1	3
271	Differential Expression of the Sphingolipid Pathway Is Associated with Sensitivity to the PP2A Activator FTY720 in Colorectal Cancer Cell Lines. Journal of Clinical Medicine, 2021, 10, 4999.	1.0	1
272	Single-Cell Analysis May Shed New Lights on the Role of LncRNAs in Chemoresistance in Gastrointestinal Cancers. RNA Technologies, 2020, , 229-253.	0.2	1
273	Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy. Cancers, 2021, 13, 49.	1.7	7
274	Cerebellar metastasis of colon cancer at diagnosis: A very rare case. Journal of Cancer Research and Therapeutics, 2022, 18, 493.	0.3	2

#	Article	IF	Citations
275	Research progress of circRNAs in chemotherapy resistance of digestive system neoplasms. World Chinese Journal of Digestology, 2021, 29, 1237-1247.	0.0	0
276	Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines. American Journal of Cancer Research, 2017, 7, 2577-2586.	1.4	1
277	Synergistically suppressive effects on colorectal cancer cells by combination of mTOR inhibitor and glycolysis inhibitor, Oxamate. International Journal of Clinical and Experimental Pathology, 2018, 11, 4439-4445.	0.5	2
278	A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer. Frontiers in Oncology, 2021, 11, 737323.	1.3	2
279	Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes. Current Oncology, 2022, 29, 209-220.	0.9	4
280	Identifies Immune Feature Genes for Prediction of Chemotherapy Benefit in Cancer. Journal of Cancer, 2022, 13, 496-507.	1.2	3
281	Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 323-330.	1.1	4
282	Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma. International Journal of Molecular Sciences, 2022, 23, 1200.	1.8	20
283	A REVIEW OF TREATMENT, RISK FACTORS, AND INCIDENCE OF COLORECTAL CANCER. International Journal of Applied Pharmaceutics, 0, , 1-6.	0.3	1
284	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
285	Ceftazidime and cefepime antagonize 5-fluorouracilâ€™s effect in colon cancer cells. BMC Cancer, 2022, 22, 125.	1.1	3
286	FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110687.	1.4	9
287	Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. Diagnostics, 2021, 11, 2308.	1.3	4
288	Effect of Zengyi Formula Combined with Chemotherapy on the Patients with Spleen Deficiency Syndrome after Operative Therapy of Colorectal Cancer. Advances in Clinical Medicine, 2022, 12, 1741-1747.	0.0	0
289	Cancer therapeutics with microbial nanotechnology-based approaches. , 2022, , 17-43.		7
290	Immunotherapy in the Treatment of Advanced Colorectal Cancer. , 2022, , 113-137.		0
291	Surgical Dilemmas Associated with Malignant Large Bowel Obstructions. Clinics in Colon and Rectal Surgery, 2022, 35, 197-203.	0.5	1
292	OXA-CuS@UiO-66-NH2 as a drug delivery system for Oxaliplatin to colorectal cancer cells. Journal of Materials Science: Materials in Medicine, 2022, 33, 26.	1.7	14

#	Article	IF	Citations
293	Advances in the use of 3D colorectal cancer models for novel drug discovery. Expert Opinion on Drug Discovery, 2022, , 1-12.	2.5	3
294	A synopsis of modern - day colorectal cancer: Where we stand. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188699.	3.3	11
295	Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patientâ€™s Stratification. Frontiers in Oncology, 2022, 12, 856575.	1.3	13
296	The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases. Cancers, 2022, 14, 1503.	1.7	10
297	Anticancer Activity of (S)-5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((pyridin-4-ylmethyl)amino)propan-2-yl)-1H-indole-2-carboxamide (RS4690), a New Dishevelled 1 Inhibitor. Cancers, 2022, 14, 1358.	4.7	4
298	7â€Dehydrocholesterol Encapsulated Polymeric Nanoparticles As a Radiationâ€Responsive Sensitizer for Enhancing Radiation Therapy. Small, 2022, , 2200710.	5.2	4
299	Immunogenic nanomedicine based on GSH-responsive nanoscale covalent organic polymers for chemo-sonodynamic therapy. Biomaterials, 2022, 283, 121428.	5.7	25
300	Synergistic antitumor activity of 5-fluorouracil and atosiban against microsatellite stable colorectal cancer through restoring GATA3. Biochemical Pharmacology, 2022, 199, 115025.	2.0	0
301	Peritoneal Metastasis: Current Status and Treatment Options. Cancers, 2022, 14, 60.	1.7	21
302	Metformin Enhancement of Therapeutic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells and Nude Mice. Biomedicines, 2022, 10, 955.	1.4	3
305	Endoscopic Stenting and Palliative Chemotherapy in Advanced Colorectal Cancer: Friends or Foes? An Analysis of the Current Literature. In Vivo, 2022, 36, 1053-1058.	0.6	4
306	Extended Lymphadenectomy for Proximal Transverse Colon Cancer: Is There a Place for Standardization?. Medicina (Lithuania), 2022, 58, 596.	0.8	3
307	5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information. Journal of Translational Medicine, 2022, 20, 209.	1.8	6
308	A novel tumor-homing TRAIL variant eradicates tumor xenografts of refractory colorectal cancer cells in combination with tumor cell-targeted photodynamic therapy. Drug Delivery, 2022, 29, 1698-1711.	2.5	5
309	Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients. Frontiers in Oncology, 0, 12, .	1.3	6
310	Formulation of two lipid-based membraneâ€“core nanoparticles for FOLFOX combination therapy. Nature Protocols, 2022, 17, 1818-1831.	5.5	10
311	Combination effects of capecitabine, irinotecan and 17-AAG on colorectal cancer cell line (HT-29). Annals of Medicine and Surgery, 2022, 78, .	0.5	2
312	Management and outcome of colorectal cancer in a resource-limited setting: Ahmadu Bello university teaching hospital, Zaria, Nigeria. Nigerian Journal of Clinical Practice, 2022, 25, 923.	0.2	2

#	Article	IF	Citations
313	Liposomal Formulations of a New Zinc(II) Complex Exhibiting High Therapeutic Potential in a Murine Colon Cancer Model. International Journal of Molecular Sciences, 2022, 23, 6728.	1.8	10
314	Optimization of Biomimetic, Leukocyte-Mimicking Nanovesicles for Drug Delivery Against Colorectal Cancer Using a Design of Experiment Approach. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	4
315	Carbon Nanotubes in Tumor-Targeted Chemotherapeutic Formulations: A Review of Opportunities and Challenges. ACS Applied Nano Materials, 2022, 5, 8649-8679.	2.4	6
316	Prognostic Models Incorporating RAS Mutation to Predict Survival in Patients with Colorectal Liver Metastases: A Narrative Review. Cancers, 2022, 14, 3223.	1.7	2
317	2D-DIGE-MS Proteomics Approaches for Identification of Gelsolin and Peroxiredoxin 4 with Lymph Node Metastasis in Colorectal Cancer. Cancers, 2022, 14, 3189.	1.7	12
318	Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy?. Updates in Surgery, 2022, 74, 1327-1335.	0.9	3
319	Long non-coding RNA PVT1: A promising chemotherapy and radiotherapy sensitizer. Frontiers in Oncology, 0, 12, .	1.3	6
320	Isolinderalactone sensitizes oxaliplatin-resistance colorectal cancer cells through JNK/p38 MAPK signaling pathways. Phytomedicine, 2022, 105, 154383.	2.3	15
321	CXCL13 Modulates Immunoactive Tumor Microenvironment and Improves Prognosis in Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
322	Therapeutic Applications of Curcumin and Derivatives in Colorectal Cancer. , 2022, 9, 51-62.		3
323	2-Nucleobase-substituted 4,6-Diaminotriazine Analogs: Synthesis and Anti-cancer Activity in 5-Fluorouracil-sensitive and Resistant Colorectal Cancer Cells. Current Medicinal Chemistry, 2023, 30, 3032-3049.	1.2	2
324	A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus) Tj ETQq1 1 0.784314 rgBT /Overloc	2.0	1
325	Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer. Biomedicines, 2022, 10, 2690.	1.4	4
326	Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy. Frontiers in Pharmacology, 0, 13, .	1.6	0
327	Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC. Pharmaceutics, 2022, 14, 2468.	2.0	1
328	Reactive oxygen species-upregulating nanomedicines towards enhanced cancer therapy. Biomaterials Science, 2023, 11, 1182-1214.	2.6	19
329	History of Treatment of Colorectal Liver Metastases. , 2022, , 3-9.		0
330	The EDN1/EDNRA/Î²â€arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation. International Journal of Oncology, 2022, 62, .	1.4	2

#	Article	IF	Citations
331	Destroying the Shield of Cancer Stem Cells: Natural Compounds as Promising Players in Cancer Therapy. Journal of Clinical Medicine, 2022, 11, 6996.	1.0	0
332	Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis. Surgery, 2023, 173, 1314-1321.	1.0	6
333	Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells. Life Sciences, 2023, 315, 121320.	2.0	2
334	Oral Spatial-to-Point Cascade Targeting â€œSugar-coated bulletsâ€•for Precise and Safe Chemotherapy by Intervention Warburg Effect. Colloids and Surfaces B: Biointerfaces, 2022, , 113108.	2.5	2
335	Prunus spinosa Extract Sensitized HCT116 Spheroids to 5-Fluorouracil Toxicity, Inhibiting Autophagy. International Journal of Molecular Sciences, 2022, 23, 16098.	1.8	1
336	Designing Synthetic, Sulfated Glycosaminoglycan Mimetics That Are Orally Bioavailable and Exhibiting In Vivo Anticancer Activity. Journal of Medicinal Chemistry, 2023, 66, 1321-1338.	2.9	3
337	DYRK2 downregulation in colorectal cancer leads to epithelialâ€“mesenchymal transition induction and chemoresistance. Scientific Reports, 2022, 12, .	1.6	3
338	Highly efficient tumor-targeted nanomedicine assembled from affibody-drug conjugate for colorectal cancer therapy. Nano Research, 2023, 16, 5256-5264.	5.8	5
339	Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis. Translational Cancer Research, 2022, 11, 4241-4253.	0.4	0
340	Increasing Dosage of Leucovorin Results in Pharmacokinetic and Gene Expression Differences When Administered as Two-Hour Infusion or Bolus Injection to Patients with Colon Cancer. Cancers, 2023, 15, 258.	1.7	0
341	The remodeling roles of lipid metabolism in colorectal cancer cells and immune microenvironment. Oncology Research, 2022, 30, 231-242.	0.6	5
342	A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients. Biomedicine and Pharmacotherapy, 2023, 159, 114272.	2.5	2
343	Hybrid lipid-polymer nanoplatform: A systematic review for targeted colorectal cancer therapy. European Polymer Journal, 2023, 186, 111877.	2.6	4
344	Ferroptosis-based drug delivery system as a new therapeutic opportunity for brain tumors. Frontiers in Oncology, 0, 13, .	1.3	5
345	Licochalcone B Induces ROS-Dependent Apoptosis in Oxaliplatin-Resistant Colorectal Cancer Cells via p38/JNK MAPK Signaling. Antioxidants, 2023, 12, 656.	2.2	2
346	Pipeline for characterizing alternative mechanisms (PCAM) based on bi-clustering to study colorectal cancer heterogeneity. Computational and Structural Biotechnology Journal, 2023, 21, 2160-2171.	1.9	0
347	Autotaxin is a novel surrogate marker for oxaliplatinâ€•related sinusoidal obstruction syndrome in patients with colorectal liver metastasis. Hepatology Research, 0, , .	1.8	0
348	Characterization of butyrate-metabolism in colorectal cancer to guide clinical treatment. Scientific Reports, 2023, 13, .	1.6	2

#	Article	IF	Citations
349	Vitamin D receptor prevents tumour development by regulating the Wnt/Î²-catenin signalling pathway in human colorectal cancer. BMC Cancer, 2023, 23, .	1.1	1
350	Flavonoids nanostructures promising therapeutic efficiencies in colorectal cancer. International Journal of Biological Macromolecules, 2023, 241, 124508.	3.6	5
351	Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World Journal of Gastrointestinal Surgery, 0, 15, 495-519.	0.8	12
371	Exploring the Role of ADME for Anticancer Prodrugs. , 2023, , 1-16.		0
374	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy, 2023, 72, 3875-3893.	2.0	4